If the patient is known to have low potassium or heart rhythm issues, monitor electrolytes
In the run-in period, all patients, regardless of whether we are randomized to receive lira or placebo later, were subject to a hypocaloric diet and exercise regime, without GLP-1 receptor agonist, with the duration of the period for each patient being the time required to lose 5% of their baseline body weight In the STEP trials (Table 1), designed to evaluate the efficacy and safety of semaglutide 2.4mg (subcutaneous, weekly) in patients with obesity, or excess weight (BMI 27kg/m2) with complications, weight loss of between 15% and 17% was achieved 68 weeks after starting treatment.7678 In one of the trials, weight loss of 10% was reported after 20 weeks of therapy
What works for one person could prove ineffective for another, leading to unpredictable results and causing cause and disappointment
10.1080/10408398.2023.2187212 166 LiaoZ
But unlike coverage for other chronic diseases, which is often comprehensive regardless of lifestyle factors, insurance policies for GLP-1s vary widely, leaving many people without access
